Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 2
2017 4
2018 3
2019 1
2020 6
2021 4
2022 6
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey.
Chamorro-de-Vega E, Romero-Jiménez R, Escudero-Vilaplana V, Ais-Larisgoitia A, Lobato Matilla ME, González CM, Menchén L, Baniandrés O, Ibares-Frias L, Lobo-Rodríguez C, Herranz-Alonso A, Sanjurjo M. Chamorro-de-Vega E, et al. J Med Internet Res. 2022 Sep 13;24(9):e37445. doi: 10.2196/37445. J Med Internet Res. 2022. PMID: 36099018 Free PMC article.
Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study.
Vicente-Valor J, Rodríguez-González C, Ferris-Villanueva M, Chamorro-de-Vega E, Romero-Jiménez R, Gómez-Costas D, Herrero-Bermejo S, Tejerina-Picado F, Osorio-Prendes S, Oarbeascoa-Royuela G, Herranz-Alonso A, Sanjurjo-Sáez M. Vicente-Valor J, et al. Among authors: chamorro de vega e. Pharmacol Rep. 2023 Oct;75(5):1254-1264. doi: 10.1007/s43440-023-00519-8. Epub 2023 Sep 1. Pharmacol Rep. 2023. PMID: 37656351
A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis.
Fernández-Cruz A, Semiglia MA, Guinea J, Martínez-Jiménez MDC, Escribano P, Kwon M, Rodríguez-Macías G, Chamorro-de-Vega E, Rodríguez-González C, Navarro R, Galar A, Sánchez-Carrillo C, Díez-Martín JL, Muñoz P. Fernández-Cruz A, et al. Among authors: chamorro de vega e. Med Mycol. 2020 Apr 1;58(3):300-309. doi: 10.1093/mmy/myz060. Med Mycol. 2020. PMID: 31231772
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid.
Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Valerio M, Amor-Garcia MA, Tejerina F, Sancho-Gonzalez M, Narrillos-Moraza A, Gimenez-Manzorro A, Manrique-Rodriguez S, Machado M, Olmedo M, Escudero-Vilaplana V, Villanueva-Bueno C, Torroba-Sanz B, Melgarejo-Ortuño A, Vicente-Valor J, Herranz A, Bouza E, Muñoz P, Sanjurjo M. Rodriguez-Gonzalez CG, et al. Among authors: chamorro de vega e. Int J Antimicrob Agents. 2021 Feb;57(2):106249. doi: 10.1016/j.ijantimicag.2020.106249. Epub 2020 Nov 28. Int J Antimicrob Agents. 2021. PMID: 33259918 Free PMC article.
Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare.
Romero-Jimenez R, Escudero-Vilaplana V, Chamorro-de-Vega E, Ais-Larisgoitia A, Lobato-Matilla E, Somoza-Fernández B, Ruiz-Briones P, González C, Baniandrés O, Menchén L, Lobo-Rodríguez C, Herranz A, Sanjurjo M. Romero-Jimenez R, et al. Among authors: chamorro de vega e. Front Immunol. 2022 Jul 28;13:915578. doi: 10.3389/fimmu.2022.915578. eCollection 2022. Front Immunol. 2022. PMID: 35967330 Free PMC article.
The Characteristics and Functionalities of Mobile Apps Aimed at Patients Diagnosed With Immune-Mediated Inflammatory Diseases: Systematic App Search.
Romero-Jimenez R, Escudero-Vilaplana V, Chamorro-De-Vega E, Ais-Larisgoitia A, Lobato Matilla ME, Herranz-Alonso A, Sanjurjo M. Romero-Jimenez R, et al. Among authors: chamorro de vega e. J Med Internet Res. 2022 Mar 4;24(3):e31016. doi: 10.2196/31016. J Med Internet Res. 2022. PMID: 35254286 Free PMC article.
Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study.
Ramírez E, Romero-Jiménez R, Hernández-Muniesa B, Fernández-Pacheco M, Calvo A, Chamorro-de-Vega E, Herrero N, Úbeda B, Morell A, Ais-Larisgoitia A, Lobato-Matilla E, Muñoz Á, Casado A, Casado MÁ, Escudero-Vilaplana V. Ramírez E, et al. Among authors: chamorro de vega e. J Clin Pharm Ther. 2022 Dec;47(12):2020-2029. doi: 10.1111/jcpt.13742. Epub 2022 Aug 5. J Clin Pharm Ther. 2022. PMID: 35929568
24 results